Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues

NCT01176357 | Unknown DMC

• 2 other identifiers: 96039FEMH-96-D-003
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Coronary artery disease (CAD), the most common type of heart disease, is caused by hardening of the arteries, or atherosclerosis that is an inflammatory process in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial trees. Epidemiological studies have found that increased cardiovascular risks are associated with increased levels of inflammatory cytokines (eg, interleukin-6 \[IL-6\] and tumor necrosis factor-alpha\[TNF-alpha\]) or their hepatic product, C-reactive protein (CRP). Higher expression of interleukin-Ibeta(IL-1beta),IL-6, monocyte chemotactic protein-1 (MCP-1), and TNF-alpha were observed in epicardial adipose tissues in patients with CAD. These findings suggested that the pericoronary tissues could be a source of inflammatory mediators or act as paracrine that lead to vascular inflammation on CAD pathogenesis. However, adiponectin, a kind of adipocytokine, produced and secreted exclusively by adipose tissue, has been reported to have a variety of anti-inflammatory functions against atherosclerosis, resulting in risk reduction for incidence of CAD events. It remains unclear whether adiponectin and inflammatory mediators in mediastinal adipose tissue contribute to CAD. We therefore aim to analyze the expression of adiponectin and inflammatory mediators in mediastinal adipose tissue between patients with CAD and with valve diseases, and to correlate these parameters with clinical atherosclerotic risks, medications (statins or antiplatelet), and blood sugar.

Conditions

Coronary Artery Disease; Atherosclerosis

Keywords

Coronary artery disease (CAD); atherosclerosis; mediastinal adipose tissue; adiponectin, inflammatory mediators

Study Arms (2)

1

CABG

2

Valve surgery

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with CAD or with valve diseases proposed to have cardiac operations

You may qualify if:

• patient underwent CABG or valve surgery in our hospital will be included

You may not qualify if:

• liver disease
• dhronic renal insufficiency
• neoplastic diseases
• taking steroids
• congestive heart failure

Sponsors & Collaborators

• Far Eastern Memorial Hospital: lead

Study Sites (1)

FEMH

Taipei, Taiwan

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Adipose tissue biopsy samples from mediastinal fat, epicardial fat, subcutaneous fat in thoracic region or abdominal region and subcutaneous fat in leg were obtained soon after sternotomy or thoracotomy before the initiation of cardiopulmonary bypass.

MeSH Terms

Conditions

Coronary Artery Disease; Atherosclerosis

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Study Officials

• Kuan-Ming Chiu, MD, PhD

  FEMH

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Kuan-Ming Chiu, MD, PhD

CONTACT

886-2-89667000

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: February 6, 2009
• First Posted: August 6, 2010
• Study Start: January 1, 2008
• Primary Completion: December 1, 2008
• Last Updated: August 6, 2010

Record last verified: 2010-08

Locations

TW (1)